376: BridgeBio’s great week and Moderna’s unraveling
The Readout Loud
00:00
Biomarin and Roctavian licensing challenge
Allison explains Biomarin's decision to out-license its hemophilia A gene therapy due to rollout difficulties.
Play episode from 07:02
Transcript
